The interplay between Angiotensin II, TLR4 and hypertension

Pharmacological Research

Volumn 120, Issue , 2017, Pages 88-96

  Biancardi, Vinicia Campana ^a   Bomfim, Gisele Facholi ^b   Reis, Wagner Luis ^c   Al Gassimi, Sarah ^d   Nunes, Kenia Pedrosa ^d  

^a AUBURN UNIVERSITY   (United States)

^b FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d Florida Institute of Technology ^*  (United States)

Author keywords

Angiotensin II; Central nervous system; Hypertension; Innate immune system; Kidney; Vasculature

Indexed keywords

ANGIOTENSIN II; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) TRANSHYDROGENASE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; TLR4 PROTEIN, HUMAN;

ALDOSTERONE RELEASE; APOPTOSIS; CELL ACTIVATION; ENCEPHALITIS; GENE EXPRESSION; GLOMERULUS FILTRATION; HOMEOSTASIS; HUMAN; HYPERTENSION; INFLAMMATION; INNATE IMMUNITY; KIDNEY BLOOD FLOW; KIDNEY TUBULE ABSORPTION; MICROGLIA; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; VASCULITIS; ADAPTIVE IMMUNITY; ANIMAL; BRAIN; COMPLICATION; IMMUNOLOGY; KIDNEY; PATHOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADAPTIVE IMMUNITY; ANGIOTENSIN II; ANIMALS; BRAIN; HUMANS; HYPERTENSION; IMMUNITY, INNATE; INFLAMMATION; KIDNEY; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 85016423417     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.03.017     Document Type: Review

References (116)

1. [1] Yoon, S.S., Gu, Q., Nwankwo, T., Wright, J.D., Hong, Y., Burt, V., Trends in blood pressure among adults with hypertension: United States, 2003 to 2012. Hypertension 65:1 (2015), 54–61.
2. [2] Brasier, A.R., Li, J., Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension 27:3 Pt 2 (1996), 465–475.
3. [3] Paul, M., Poyan Mehr, A., Kreutz, R., Physiology of local renin-angiotensin systems. Physiol. Rev. 86:3 (2006), 747–803.
4. [4] Mian, M.O., Paradis, P., Schiffrin, E.L., Innate immunity in hypertension. Curr. Hypertens. Rep., 16(2), 2014, 413.
5. [5] Singh, M.V., Abboud, F.M., Toll-like receptors and hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 307:5 (2014), R501–R504.
6. [6] McMaster, W.G., Kirabo, A., Madhur, M.S., Harrison, D.G., Inflammation, immunity, and hypertensive end-organ damage. Circ. Res. 116:6 (2015), 1022–1033.
7. [7] McCarthy, C.G., Goulopoulou, S., Wenceslau, C.F., Spitler, K., Matsumoto, T., Webb, R.C., Toll-like receptors and damage-associated molecular patterns: novel links between inflammation and hypertension. Am. J. Physiol. Heart Circ. Physiol. 306:2 (2014), H184–H196.
8. [8] Akira, S., Takeda, K., Toll-like receptor signalling. Nat. Rev. Immunol. 4:7 (2004), 499–511.
9. [9] Bomfim, G.F., Dos Santos, R.A., Oliveira, M.A., Giachini, F.R., Akamine, E.H., Tostes, R.C., Fortes, Z.B., Webb, R.C., Carvalho, M.H., Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin. Sci. (Lond) 122:11 (2012), 535–543.
10. [10] Marchesi, C., Paradis, P., Schiffrin, E.L., Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol. Sci. 29:7 (2008), 367–374.
11. [11] Sanz-Rosa, D., Oubina, M.P., Cediel, E., de Las Heras, N., Vegazo, O., Jimenez, J., Lahera, V., Cachofeiro, V., Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am. J. Physiol. Heart Circ. Physiol. 288:1 (2005), H111–H115.
12. [12] Brands, M.W., Banes-Berceli, A.K., Inscho, E.W., Al-Azawi, H., Allen, A.J., Labazi, H., Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation. Hypertension 56:5 (2010), 879–884.
13. [13] Zhang, W., Wang, W., Yu, H., Zhang, Y., Dai, Y., Ning, C., Tao, L., Sun, H., Kellems, R.E., Blackburn, M.R., Xia, Y., Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension 59:1 (2012), 136–144.
14. [14] Chamarthi, B., Williams, G.H., Ricchiuti, V., Srikumar, N., Hopkins, P.N., Luther, J.M., Jeunemaitre, X., Thomas, A., Inflammation and hypertension: the interplay of interleukin-6, dietary sodium, and the renin-angiotensin system in humans. Am. J. Hypertens. 24:10 (2011), 1143–1148.
15. [15] Kang, Y.M., Ma, Y., Zheng, J.P., Elks, C., Sriramula, S., Yang, Z.M., Francis, J., Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension. Cardiovasc. Res. 82:3 (2009), 503–512.
16. [16] Sriramula, S., Cardinale, J.P., Francis, J., Inhibition of TNF in the brain reverses alterations in RAS components and attenuates angiotensin II-induced hypertension. PLoS One, 8(5), 2013, e63847.
17. [17] Schiffrin, E.L., Touyz, R.M., Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade. J. Am. Coll. Cardiol. 42:5 (2003), 911–913.
18. [18] Tschudi, M.R., Mesaros, S., Luscher, T.F., Malinski, T., Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Increased decomposition by superoxide in hypertension. Hypertension 27:1 (1996), 32–35.
19. [19] Ruiz-Ortega, M., Lorenzo, O., Ruperez, M., Konig, S., Wittig, B., Egido, J., Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ. Res. 86:12 (2000), 1266–1272.
20. [20] Yogi, A., Mercure, C., Touyz, J., Callera, G.E., Montezano, A.C., Aranha, A.B., Tostes, R.C., Reudelhuber, T., Touyz, R.M., Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension. Hypertension 51:2 (2008), 500–506.
21. [21] Sun, C., Sellers, K.W., Sumners, C., Raizada, M.K., NAD(P)H oxidase inhibition attenuates neuronal chronotropic actions of angiotensin II. Circ. Res. 96:6 (2005), 659–666.
22. [22] Gao, L., Wang, W., Li, Y.L., Schultz, H.D., Liu, D., Cornish, K.G., Zucker, I.H., Sympathoexcitation by central ANG II: roles for AT1 receptor upregulation and NAD(P)H oxidase in RVLM. Am. J. Physiol. Heart Circ. Physiol. 288:5 (2005), H2271–H2279.
23. [23] Lob, H.E., Marvar, P.J., Guzik, T.J., Sharma, S., McCann, L.A., Weyand, C., Gordon, F.J., Harrison, D.G., Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension 55:2 (2010), 277–283 6p following 283.
24. [24] Abais-Battad, J.M., Rudemiller, N.P., Mattson, D.L., Hypertension and immunity: mechanisms of T cell activation and pathways of hypertension. Curr. Opin. Nephrol. Hypertens. 24:5 (2015), 470–474.
25. [25] Singh, M.V., Chapleau, M.W., Harwani, S.C., Abboud, F.M., The immune system and hypertension. Immunol. Res. 59:1–3 (2014), 243–253.
26. [26] Sparks, M.A., Crowley, S.D., Gurley, S.B., Mirotsou, M., Coffman, T.M., Classical Renin-Angiotensin system in kidney physiology. Compr. Physiol. 4:3 (2014), 1201–1228.
27. [27] Munoz-Durango, N., Fuentes, C.A., Castillo, A.E., Gonzalez-Gomez, L.M., Vecchiola, A., Fardella, C.E., Kalergis, A.M., Role of the renin-angiotensin-aldosterone system beyond blood pressure regulation: molecular and cellular mechanisms involved in end-organ damage during arterial hypertension. Int. J. Mol. Sci., 17(7), 2016.
28. [28] Kobori, H., Nangaku, M., Navar, L.G., Nishiyama, A., The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 59:3 (2007), 251–287.
29. [29] Bidani, A.K., Griffin, K.A., Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 44:5 (2004), 595–601.
30. [30] Lodha, S., Dani, D., Mehta, R., Bhaskaran, M., Reddy, K., Ding, G., Singhal, P.C., Angiotensin II-induced mesangial cell apoptosis: role of oxidative stress. Mol. Med. 8:12 (2002), 830–840.
31. [31] Wolf, G., Bohlender, J., Bondeva, T., Roger, T., Thaiss, F., Wenzel, U.O., Angiotensin II upregulates toll-like receptor 4 on mesangial cells. J. Am. Soc. Nephrol. 17:6 (2006), 1585–1593.
32. [32] Wolf, G., Role of reactive oxygen species in angiotensin II-mediated renal growth, differentiation, and apoptosis. Antioxid. Redox. Signal 7:9–10 (2005), 1337–1345.
33. [33] Sugiyama, H., Kashihara, N., Makino, H., Role of apoptosis in renal injury. Nihon Rinsho 54:7 (1996), 1975–1981.
34. [34] Dikalov, S.I., Nazarewicz, R.R., Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease. Antioxid. Redox. Signal 19:10 (2013), 1085–1094.
35. [35] Wolf, G., Wenzel, U., Burns, K.D., Harris, R.C., Stahl, R.A., Thaiss, F., Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney Int. 61:6 (2002), 1986–1995.
36. [36] Frantz, S., Ertl, G., Bauersachs, J., Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 4:8 (2007), 444–454.
37. [37] Spirig, R., Tsui, J., Shaw, S., The emerging role of TLR and innate immunity in cardiovascular disease. Cardiol. Res. Pract., 2012, 2012, 181394.
38. [38] Zhang, B., Ramesh, G., Uematsu, S., Akira, S., Reeves, W.B., TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J. Am. Soc. Nephrol. 19:5 (2008), 923–932.
39. [39] Campbell, M.T., Hile, K.L., Zhang, H., Asanuma, H., Vanderbrink, B.A., Rink, R.R., Meldrum, K.K., Toll-like receptor 4: a novel signaling pathway during renal fibrogenesis. J. Surg. Res. 168:1 (2011), e61–e69.
40. [40] Souza, A.C., Tsuji, T., Baranova, I.N., Bocharov, A.V., Wilkins, K.J., Street, J.M., Alvarez-Prats, A., Hu, X., Eggerman, T., Yuen, P.S., Star, R.A., TLR4 mutant mice are protected from renal fibrosis and chronic kidney disease progression Physiol. Rep., 3(9), 2015.
41. [41] Erridge, C., Endogenous ligands of TLR2 and TLR4: agonists or assistants?. J. Leukoc. Biol. 87:6 (2010), 989–999.
42. [42] Nair, A.R., Ebenezer, P.J., Saini, Y., Francis, J., Angiotensin II-induced hypertensive renal inflammation is mediated through HMGB1-TLR4 signaling in rat tubulo-epithelial cells. Exp. Cell Res. 335:2 (2015), 238–247.
43. [43] Anders, H.J., Banas, B., Schlondorff, D., Signaling danger: toll-like receptors and their potential roles in kidney disease. J. Am. Soc. Nephrol. 15:4 (2004), 854–867.
44. [44] Dasu, M.R., Riosvelasco, A.C., Jialal, I., Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis 202:1 (2009), 76–83.
45. [45] Lv, J., Jia, R., Yang, D., Zhu, J., Ding, G., Candesartan attenuates Angiotensin II-induced mesangial cell apoptosis via TLR4/MyD88 pathway. Biochem. Biophys. Res. Commun. 380:1 (2009), 81–86.
46. [46] Zhang, Y., Peng, W., Ao, X., Dai, H., Yuan, L., Huang, X., Zhou, Q., TAK-242, a toll-like receptor 4 antagonist, protects against aldosterone-induced cardiac and renal injury. PLoS ONE, 10(11), 2015, e0142456.
47. [47] Yang, H., Wang, H., Chavan, S.S., Andersson, U., High mobility group box protein 1 (HMGB1): the prototypical endogenous danger molecule. Mol. Med. 21:Suppl 1 (2015), S6–S12.
48. [48] Akishita, M., Horiuchi, M., Yamada, H., Zhang, L., Shirakami, G., Tamura, K., Ouchi, Y., Dzau, V.J., Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol. Genomics 2:1 (2000), 13–20.
49. [49] Montezano, A.C., Nguyen Dinh Cat, A., Rios, F.J., Touyz, R.M., Angiotensin II and vascular injury. Curr. Hypertens. Rep., 16(6), 2014, 431.
50. [50] Pacurari, M., Kafoury, R., Tchounwou, P.B., Ndebele, K., The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling. Int. J. Inflam., 2014, 2014, 689360.
51. [51] Suzuki, Y., Ruiz-Ortega, M., Lorenzo, O., Ruperez, M., Esteban, V., Egido, J., Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. 35:6 (2003), 881–900.
52. [52] Touyz, R.M., Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr. Opin. Nephrol. Hypertens. 14:2 (2005), 125–131.
53. [53] Ji, Y., Liu, J., Wang, Z., Liu, N., Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell. Physiol. Biochem. 23:4–6 (2009), 265–276.
54. [54] Hernanz, R., Martinez-Revelles, S., Palacios, R., Martin, A., Cachofeiro, V., Aguado, A., Garcia-Redondo, L., Barrus, M.T., de Batista, P.R., Briones, A.M., Salaices, M., Alonso, M.J., Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension. Br. J. Pharmacol., 2015.
55. [55] Bomfim, G.F., Echem, C., Martins, C.B., Costa, T.J., Sartoretto, S.M., Dos Santos, R.A., Oliveira, M.A., Akamine, E.H., Fortes, Z.B., Tostes, R.C., Webb, R.C., Carvalho, M.H., Toll-like receptor 4 inhibition reduces vascular inflammation in spontaneously hypertensive rats. Life Sci. 122 (2015), 1–7.
56. [56] De Batista, P.R., Palacios, R., Martin, A., Hernanz, R., Medici, C.T., Silva, M.A., Rossi, E.M., Aguado, A., Vassallo, D.V., Salaices, M., Alonso, M.J., Toll-like receptor 4 upregulation by angiotensin II contributes to hypertension and vascular dysfunction through reactive oxygen species production. PLoS One, 9(8), 2014, e104020.
57. [57] Nakashima, T., Umemoto, S., Yoshimura, K., Matsuda, S., Itoh, S., Murata, T., Fukai, T., Matsuzaki, M., TLR4 is a critical regulator of angiotensin II-induced vascular remodeling: the roles of extracellular SOD and NADPH oxidase. Hypertens. Res. 38:10 (2015), 649–655.
58. [58] Sollinger, D., Eissler, R., Lorenz, S., Strand, S., Chmielewski, S., Aoqui, C., Schmaderer, C., Bluyssen, H., Zicha, J., Witzke, O., Scherer, E., Lutz, J., Heemann, U., Baumann, M., Damage-associated molecular pattern activated Toll-like receptor 4 signalling modulates blood pressure in L-NAME-induced hypertension. Cardiovasc. Res. 101:3 (2014), 464–472.
59. [59] McKinley, M.J., Badoer, E., Oldfield, B.J., Intravenous angiotensin II induces Fos-immunoreactivity in circumventricular organs of the lamina terminalis. Brain Res. 594:2 (1992), 295–300.
60. [60] Premer, C., Lamondin, C., Mitzey, A., Speth, R.C., Brownfield, M.S., Immunohistochemical localization of AT1a, AT1b, and AT2 Angiotensin II receptor subtypes in the rat adrenal, pituitary, and brain with a perspective commentary. Int. J. Hypertens., 2013, 2013, 175428.
61. [61] McKinley, M.J., McAllen, R.M., Pennington, G.L., Smardencas, A., Weisinger, R.S., Oldfield, B.J., Physiological actions of angiotensin II mediated by AT1 and AT2 receptors in the brain. Clin. Exp. Pharmacol. Physiol. Suppl. 3 (1996), S99–S104.
62. [62] Nguyen, G., Delarue, F., Burckle, C., Bouzhir, L., Giller, T., Sraer, J.D., Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109:11 (2002), 1417–1427.
63. [63] Shan, Z., Shi, P., Cuadra, A.E., Dong, Y., Lamont, G.J., Li, Q., Seth, D.M., Navar, L.G., Katovich, M.J., Sumners, C., Raizada, M.K., Involvement of the brain (pro)renin receptor in cardiovascular homeostasis. Circ. Res. 107:7 (2010), 934–938.
64. [64] Ueno, M., Sakamoto, H., Liao, Y.J., Onodera, M., Huang, C.L., Miyanaka, H., Nakagawa, T., Blood-brain barrier disruption in the hypothalamus of young adult spontaneously hypertensive rats. Histochem. Cell. Biol. 122:2 (2004), 131–137.
65. [65] Vital, S.A., Terao, S., Nagai, M., Granger, D.N., Mechanisms underlying the cerebral microvascular responses to angiotensin II-induced hypertension. Microcirculation 17:8 (2010), 641–649.
66. [66] Pelisch, N., Hosomi, N., Mori, H., Masaki, T., Nishiyama, A., RAS inhibition attenuates cognitive impairment by reducing blood- brain barrier permeability in hypertensive subjects. Curr. Hypertens. Rev. 9:2 (2013), 93–98.
67. [67] Pelisch, N., Hosomi, N., Ueno, M., Nakano, D., Hitomi, H., Mogi, M., Shimada, K., Kobori, H., Horiuchi, M., Sakamoto, H., Matsumoto, M., Kohno, M., Nishiyama, A., Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats. Am. J. Hypertens. 24:3 (2011), 362–368.
68. [68] Biancardi, V.C., Son, S.J., Ahmadi, S., Filosa, J.A., Stern, J.E., Circulating angiotensin II gains access to the hypothalamus and brain stem during hypertension via breakdown of the blood-brain barrier. Hypertension 63:3 (2014), 572–579.
69. [69] Capone, C., Faraco, G., Peterson, J.R., Coleman, C., Anrather, J., Milner, T.A., Pickel, V.M., Davisson, R.L., Iadecola, C., Central cardiovascular circuits contribute to the neurovascular dysfunction in angiotensin II hypertension. J. Neurosci. 32:14 (2012), 4878–4886.
70. [70] Young, C.N., Davisson, R.L., Angiotensin-II, the brain, and hypertension: an update. Hypertension 66:5 (2015), 920–926.
71. [71] Reis, W.L., Saad, W.A., Camargo, L.A., Elias, L.L., Antunes-Rodrigues, J., Central nitrergic system regulation of neuroendocrine secretion, fluid intake and blood pressure induced by angiotensin-II. Behav. Brain Funct., 6, 2010, 64.
72. [72] Zubcevic, J., Waki, H., Raizada, M.K., Paton, J.F., Autonomic-immune-vascular interaction: an emerging concept for neurogenic hypertension. Hypertension 57:6 (2011), 1026–1033.
73. [73] Harrison, D.G., Guzik, T.J., Lob, H.E., Madhur, M.S., Marvar, P.J., Thabet, S.R., Vinh, A., Weyand, C.M., Inflammation, immunity, and hypertension. Hypertension 57:2 (2011), 132–140.
74. [74] Perry, V.H., Nicoll, J.A., Holmes, C., Microglia in neurodegenerative disease. Nat. Rev. Neurol. 6:4 (2010), 193–201.
75. [75] Appel, S.H., Beers, D.R., Henkel, J.S., T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?. Trends Immunol. 31:1 (2010), 7–17.
76. [76] Lopes Pinheiro, M.A., Kooij, G., Mizee, M.R., Kamermans, A., Enzmann, G., Lyck, R., Schwaninger, M., Engelhardt, B., de Vries, H.E., Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke. Biochim. Biophys. Acta 1862:3 (2016), 461–471.
77. [77] Kettenmann, H., Hanisch, U.K., Noda, M., Verkhratsky, A., Physiology of microglia. Physiol. Rev. 91:2 (2011), 461–553.
78. [78] Block, M.L., Zecca, L., Hong, J.S., Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8:1 (2007), 57–69.
79. [79] Shi, P., Diez-Freire, C., Jun, J.Y., Qi, Y., Katovich, M.J., Li, Q., Sriramula, S., Francis, J., Sumners, C., Raizada, M.K., Brain microglial cytokines in neurogenic hypertension. Hypertension 56:2 (2010), 297–303.
80. [80] Biancardi, V.C., Stranahan, A.M., Krause, E.G., de Kloet, A.D., Stern, J.E., Cross talk between AT1 receptors and Toll-like receptor 4 in microglia contributes to angiotensin II-derived ROS production in the hypothalamic paraventricular nucleus. Am. J. Physiol. Heart Circ. Physiol. 310:3 (2016), H404–H415.
81. [81] Shen, X.Z., Li, Y., Li, L., Shah, K.H., Bernstein, K.E., Lyden, P., Shi, P., Microglia participate in neurogenic regulation of hypertension. Hypertension 66:2 (2015), 309–316.
82. [82] Saijo, K., Glass, C.K., Microglial cell origin and phenotypes in health and disease. Nat. Rev. Immunol. 11:11 (2011), 775–787.
83. [83] Lehnardt, S., Massillon, L., Follett, P., Jensen, F.E., Ratan, R., Rosenberg, P.A., Volpe, J.J., Vartanian, T., Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. U. S. A. 100:14 (2003), 8514–8519.
84. [84] Benicky, J., Sanchez-Lemus, E., Pavel, J., Saavedra, J.M., Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell. Mol. Neurobiol. 29:6–7 (2009), 781–792.
85. [85] Benicky, J., Sanchez-Lemus, E., Honda, M., Pang, T., Orecna, M., Wang, J., Leng, Y., Chuang, D.M., Saavedra, J.M., Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 36:4 (2011), 857–870.
86. [86] Dange, R.B., Agarwal, D., Masson, G.S., Vila, J., Wilson, B., Nair, A., Francis, J., Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension. Cardiovasc. Res. 103:1 (2014), 17–27.
87. [87] Li, H.B., Li, X., Huo, C.J., Su, Q., Guo, J., Yuan, Z.Y., Zhu, G.Q., Shi, X.L., Liu, J.J., Kang, Y.M., TLR4/MyD88/NF-kappaB signaling and PPAR-gamma within the paraventricular nucleus are involved in the effects of telmisartan in hypertension. Toxicol. Appl. Pharmacol. 305 (2016), 93–102.
88. [88] Dange, R.B., Agarwal, D., Teruyama, R., Francis, J., Toll-like receptor 4 inhibition within the paraventricular nucleus attenuates blood pressure and inflammatory response in a genetic model of hypertension. J. Neuroinflammation, 12, 2015, 31.
89. [89] Masson, G.S., Nair, A.R., Dange, R.B., Silva-Soares, P.P., Michelini, L.C., Francis, J., Toll-like receptor 4 promotes autonomic dysfunction, inflammation and microglia activation in the hypothalamic paraventricular nucleus: role of endoplasmic reticulum stress. PLoS ONE, 10(3), 2015, e0122850.
90. [90] Young, C.N., Cao, X., Guruju, M.R., Pierce, J.P., Morgan, D.A., Wang, G., Iadecola, C., Mark, A.L., Davisson, R.L., ER stress in the brain subfornical organ mediates angiotensin-dependent hypertension. J. Clin. Invest. 122:11 (2012), 3960–3964.
91. [91] Chao, Y.M., Lai, M.D., Chan, J.Y., Redox-sensitive endoplasmic reticulum stress and autophagy at rostral ventrolateral medulla contribute to hypertension in spontaneously hypertensive rats. Hypertension 61:6 (2013), 1270–1280.
92. [92] Zimmerman, M.C., Lazartigues, E., Lang, J.A., Sinnayah, P., Ahmad, I.M., Spitz, D.R., Davisson, R.L., Superoxide mediates the actions of angiotensin II in the central nervous system. Circ. Res. 91:11 (2002), 1038–1045.
93. [93] Zimmerman, M.C., Lazartigues, E., Sharma, R.V., Davisson, R.L., Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ. Res. 95:2 (2004), 210–216.
94. [94] Rodriguez-Perez, A.I., Borrajo, A., Rodriguez-Pallares, J., Guerra, M.J., Labandeira-Garcia, J.L., Interaction between NADPH-oxidase and Rho-kinase in angiotensin II-induced microglial activation. Glia 63:3 (2015), 466–482.
95. [95] Joglar, B., Rodriguez-Pallares, J., Rodriguez-Perez, A.I., Rey, P., Guerra, M.J., Labandeira-Garcia, J.L., The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J. Neurochem. 109:2 (2009), 656–669.
96. [96] Rodriguez-Pallares, J., Rey, P., Parga, J.A., Munoz, A., Guerra, M.J., Labandeira-Garcia, J.L., Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol. Dis. 31:1 (2008), 58–73.
97. [97] Su, Q., Qin, D.N., Wang, F.X., Ren, J., Li, H.B., Zhang, M., Yang, Q., Miao, Y.W., Yu, X.J., Qi, J., Zhu, Z., Zhu, G.Q., Kang, Y.M., Inhibition of reactive oxygen species in hypothalamic paraventricular nucleus attenuates the renin-angiotensin system and proinflammatory cytokines in hypertension. Toxicol. Appl. Pharmacol. 276:2 (2014), 115–120.
98. [98] Wu, K.L., Chan, S.H., Chan, J.Y., Neuroinflammation and oxidative stress in rostral ventrolateral medulla contribute to neurogenic hypertension induced by systemic inflammation. J. Neuroinflammation, 9, 2012, 212.
99. [99] Fleegal-DeMotta, M.A., Doghu, S., Banks, W.A., Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells. J. Cereb. Blood Flow Metab. 29:3 (2009), 640–647.
100. [100] Zhang, M., Mao, Y., Ramirez, S.H., Tuma, R.F., Chabrashvili, T., Angiotensin II induced cerebral microvascular inflammation and increased blood-brain barrier permeability via oxidative stress. Neuroscience 171:3 (2010), 852–858.
101. [101] Sumi, N., Nishioku, T., Takata, F., Matsumoto, J., Watanabe, T., Shuto, H., Yamauchi, A., Dohgu, S., Kataoka, Y., Lipopolysaccharide-activated microglia induce dysfunction of the blood-brain barrier in rat microvascular endothelial cells co-cultured with microglia. Cell. Mol. Neurobiol. 30:2 (2010), 247–253.
102. [102] Kacimi, R., Giffard, R.G., Yenari, M.A., Endotoxin-activated microglia injure brain derived endothelial cells via NF-kappaB, JAK-STAT and JNK stress kinase pathways. J. Inflamm. (Lond), 8, 2011, 7.
103. [103] Kang, Y.M., Yang, Q., Yu, X.J., Qi, J., Zhang, Y., Li, H.B., Su, Q., Zhu, G.Q., Hypothalamic paraventricular nucleus activation contributes to neurohumoral excitation in rats with heart failure. Regen. Med. Res., 2(1), 2014, 2.
104. [104] Te Riet, L., van Esch, J.H., Roks, A.J., van den Meiracker, A.H., Danser, A.H., Hypertension: renin-angiotensin-aldosterone system alterations. Circ. Res. 116:6 (2015), 960–975.
105. [105] Bondeva, T., Roger, T., Wolf, G., Differential regulation of Toll-like receptor 4 gene expression in renal cells by angiotensin II: dependency on AP1 and PU.1 transcriptional sites. Am. J. Nephrol. 27:3 (2007), 308–314.
106. [106] Tang, S.C., Lai, K.N., The pathogenic role of the renal proximal tubular cell in diabetic nephropathy. Nephrol. Dial. Transplant. 27:8 (2012), 3049–3056.
107. [107] Yu, D., Shi, M., Bao, J., Yu, X., Li, Y., Liu, W., Genipin ameliorates hypertension-induced renal damage via the angiotensin II-TLR/MyD88/MAPK pathway. Fitoterapia 112 (2016), 244–253.
108. [108] Wu, J., Yang, X., Zhang, Y.F., Zhou, S.F., Zhang, R., Dong, X.Q., Fan, J.J., Liu, M., Yu, X.Q., Angiotensin II upregulates Toll-like receptor 4 and enhances lipopolysaccharide-induced CD40 expression in rat peritoneal mesothelial cells. Inflamm. Res. 58:8 (2009), 473–482.
109. [109] Roger, T., Miconnet, I., Schiesser, A.L., Kai, H., Miyake, K., Calandra, T., Critical role for Ets, AP-1 and GATA-like transcription factors in regulating mouse Toll-like receptor 4 (Tlr4) gene expression. Biochem. J. 387:Pt 2 (2005), 355–365.
110. [110] Dai, Q., Xu, M., Yao, M., Sun, B., Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br. J. Pharmacol. 152:7 (2007), 1042–1048.
111. [111] Saito, Y., Berk, B.C., Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors. J. Mol. Cell. Cardiol. 33:1 (2001), 3–7.
112. [112] De, S., Zhou, H., DeSantis, D., Croniger, C.M., Li, X., Stark, G.R., Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal. Proc. Natl. Acad. Sci. U. S. A. 112:31 (2015), 9680–9685.
113. [113] Hernanz, R., Martinez-Revelles, S., Palacios, R., Martin, A., Cachofeiro, V., Aguado, A., Garcia-Redondo, L., Barrus, M.T., de Batista, P.R., Briones, A.M., Salaices, M., Alonso, M.J., Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension. Br. J. Pharmacol. 172:12 (2015), 3159–3176.
114. [114] Berk, B.C., Angiotensin type 2 receptor (AT2R): a challenging twin. Sci. STKE, 2003(181), 2003, PE16.
115. [115] Seong, S.Y., Matzinger, P., Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4:6 (2004), 469–478.
116. [116] de Graaf, R., Kloppenburg, G., Kitslaar, P.J., Bruggeman, C.A., Stassen, F., Human heat shock protein 60 stimulates vascular smooth muscle cell proliferation through Toll-like receptors 2 and 4. Microbes Infect. 8:7 (2006), 1859–1865.